Dordaviprone; Modeyso Cancer Research Results

ONC201, Dordaviprone; Modeyso: Click to Expand ⟱
Features:

ONC201 (Dordaviprone; Modeyso) — Orally active, brain-penetrant imipridone anticancer drug with dual activity as an allosteric agonist of the mitochondrial protease ClpP and antagonist of dopamine D2/D3 receptors (DRD2/DRD3). ONC201 disrupts mitochondrial metabolism, activates cellular stress responses, suppresses pro-survival signaling, and promotes tumor-cell apoptosis.

Drug class: Targeted anticancer therapy / mitochondrial protease activator / imipridone. ONC201 is an antineoplastic drug but is not conventional cytotoxic chemotherapy.

Primary cancer relevance: Strongest for diffuse midline glioma harboring an H3 K27M mutation. In August 2025, dordaviprone received FDA accelerated approval for adult and pediatric patients age 1 year and older with progressive H3 K27M-mutant diffuse midline glioma following prior therapy.

Primary mechanism: ClpP activation → mitochondrial proteolysis and metabolic dysfunction ↑ → integrated stress response ↑ → apoptosis ↑. ONC201 also antagonizes DRD2/DRD3 and can suppress downstream AKT and MAPK/ERK survival signaling.

Typical target/pathway effects: CLPP activation ↑; DRD2 antagonism; DRD3 antagonism; mitochondrial respiration/metabolism ↓; integrated stress response ↑; ATF4 ↑; CHOP/DDIT3 ↑; AKT signaling ↓; MAPK/ERK signaling ↓; apoptosis ↑; tumor-cell proliferation ↓.

H3 K27M relevance: H3 K27M-mutant diffuse midline glioma appears particularly sensitive to ONC201/dordaviprone. Treatment has been associated with restoration of H3K27 trimethylation and durable responses in a subset of patients.

Clinical evidence: FDA accelerated approval was based on an integrated population of patients with recurrent/progressive H3 K27M-mutant diffuse midline glioma. The objective response rate was approximately 22%, with a median response duration of approximately 10.3 months.

Typical adult clinical dose: 625 mg orally once weekly for the FDA-approved indication.



Scientific Papers found: Click to Expand⟱
8641- MBZ,  ONC201,    The therapeutic potential of repurposed mebendazole, alone and in synergistic combination with ONC201, in the treatment of diffuse midline glioma
- in-vitro, GBM, NA
TumCCA↑, P21↑, p27/CDKN1B↑, Apoptosis↑, Casp3↑, cl‑PARP↑, Synergy↑, ChemoSen↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Casp3↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↑, 1,   p27/CDKN1B↑, 1,   TumCCA↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Synergy↑, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:492  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page